<DOC>
	<DOCNO>NCT00333294</DOCNO>
	<brief_summary>The objective study determine wether ZD1839 associate radiotherapy , begin chemotherapy effective treatment disease evaluate tolerance treatment .</brief_summary>
	<brief_title>Phase II Iressa + Irradiation Followed Chemo NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed informed consent . 18 75 year inclusive . At least one measurable lesion histologically confirm inoperable stage III NSCLC . WHO performance status 0 2 inclusive . Adequate pulmonary function , pulmonary dose volume histogram less equal 40 % . Life expectancy least 6 month . Using secure contraceptive precaution . Any previous anti cancer therapy NSCLC . Known severe hypersensitivity product Any evidence clinically active interstitial lung disease Other coexist malignancy , symptomatic metastasis . Abnormal blood test Weight loss 15 % 3 month start study . Treatment nonapproved investigational drug within 30 day Day 1 study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>